As of Nov 2, 2026: 17 stocks, 3 scored.

Small-cap biotech stocks

17 stocks · Healthcare sector

Drug developers worth under $2 billion with an FDA decision or Phase 3 trial data due soon.

Average score-3.5Poor Stocks17scored Today-1.8%on average

As of 3:57 PM ET, delayed 15+ min · Live for Pro members

Small-cap biotech stocks with catalysts, ranked by Quality Score

The theme's stocks
Stock	What it does	Price	Today	Market cap	Quality Score
VIRVir Biotechnology	Tests tobevibart and elebsiran for hepatitis delta in the ECLIPSE trials.	$11.04-2.30%	-2.30%	$2.0B	5
Tests tobevibart and elebsiran for hepatitis delta in the ECLIPSE trials.
Tests tobevibart and elebsiran for hepatitis delta in the ECLIPSE trials.
BHVNBiohaven	Tests opakalim for focal epilepsy in the RISE 2 and RISE 3 trials.	$15.17-1.65%	-1.65%	$2.5B	1
Tests opakalim for focal epilepsy in the RISE 2 and RISE 3 trials.
Tests opakalim for focal epilepsy in the RISE 2 and RISE 3 trials.
AGIOAgios Pharmaceuticals	Develops mitapivat for blood disorders, including sickle cell disease.	$29.99-1.83%	-1.83%	$2.2B	1
Develops mitapivat for blood disorders, including sickle cell disease.
Develops mitapivat for blood disorders, including sickle cell disease.
FDA decision ahead 6
FDA decision ahead 6
FDA decision ahead 6
FDA decision ahead 6
CAPRCapricor Therapeutics	Develops Deramiocel, a cell therapy for Duchenne muscular dystrophy.	$7.27+13.87%	+13.87%	$385M
Develops Deramiocel, a cell therapy for Duchenne muscular dystrophy.
Develops Deramiocel, a cell therapy for Duchenne muscular dystrophy.
MLYSMineralys Therapeutics	Seeks FDA approval of lorundrostat for high blood pressure.	$15.61-14.16%	-14.16%	$1.9B
Seeks FDA approval of lorundrostat for high blood pressure.
Seeks FDA approval of lorundrostat for high blood pressure.
NRXPNRX Pharmaceuticals	Develops ketamine drugs, including KETAFREE, a generic awaiting FDA approval.	$2.18-4.18%	-4.18%	$115M
Develops ketamine drugs, including KETAFREE, a generic awaiting FDA approval.
Develops ketamine drugs, including KETAFREE, a generic awaiting FDA approval.
NUVBNuvation Bio	Sells IBTROZI for a form of lung cancer and tests safusidenib in glioma.	$4.62-2.94%	-2.94%	$1.7B
Sells IBTROZI for a form of lung cancer and tests safusidenib in glioma.
Sells IBTROZI for a form of lung cancer and tests safusidenib in glioma.
SVRASavara	Develops MOLBREEVI, an inhaled drug for the lung disease autoimmune PAP.	$4.72-2.07%	-2.07%	$1.0B
Develops MOLBREEVI, an inhaled drug for the lung disease autoimmune PAP.
Develops MOLBREEVI, an inhaled drug for the lung disease autoimmune PAP.
VNDAVanda Pharmaceuticals	Seeks FDA approval of imsidolimab for the skin disease GPP.	$3.88+2.37%	+2.37%	$245M
Seeks FDA approval of imsidolimab for the skin disease GPP.
Seeks FDA approval of imsidolimab for the skin disease GPP.
Phase 3 data ahead 8
Phase 3 data ahead 8
Phase 3 data ahead 8
Phase 3 data ahead 8
ACHVAchieve Life Sciences	Tests cytisinicline to help people quit vaping, in a Phase 3 trial.	$6.64-2.86%	-2.86%	$741M
Tests cytisinicline to help people quit vaping, in a Phase 3 trial.
Tests cytisinicline to help people quit vaping, in a Phase 3 trial.
ANNXAnnexon	Develops tanruprubart, a drug for the nerve disease Guillain-Barré syndrome.	$3.94-2.72%	-2.72%	$760M
Develops tanruprubart, a drug for the nerve disease Guillain-Barré syndrome.
Develops tanruprubart, a drug for the nerve disease Guillain-Barré syndrome.
IMUXImmunic	Tests vidofludimus calcium in two Phase 3 trials in relapsing MS.	$7.38-1.73%	-1.73%	$106M
Tests vidofludimus calcium in two Phase 3 trials in relapsing MS.
Tests vidofludimus calcium in two Phase 3 trials in relapsing MS.
LXRXLexicon Pharmaceuticals	Tests sotagliflozin in the heart disease HCM, in the SONATA-HCM trial.	$1.44+1.06%	+1.06%	$659M
Tests sotagliflozin in the heart disease HCM, in the SONATA-HCM trial.
Tests sotagliflozin in the heart disease HCM, in the SONATA-HCM trial.
MLTXMoonLake Immunotherapeutics	Tests sonelokimab in psoriatic arthritis in the Phase 3 IZAR trials.	$11.48-2.55%	-2.55%	$1.1B
Tests sonelokimab in psoriatic arthritis in the Phase 3 IZAR trials.
Tests sonelokimab in psoriatic arthritis in the Phase 3 IZAR trials.
OCSOculis	Tests licaminlimab for dry eye disease in the Phase 2/3 PREDICT-1 trial.	$7.71-6.72%	-6.72%	$507M
Tests licaminlimab for dry eye disease in the Phase 2/3 PREDICT-1 trial.
Tests licaminlimab for dry eye disease in the Phase 2/3 PREDICT-1 trial.
OCULOcular Therapeutix	Tests AXPAXLI, an eye implant for wet AMD, in the Phase 3 SOL-R trial.	$6.75-3.23%	-3.23%	$1.6B
Tests AXPAXLI, an eye implant for wet AMD, in the Phase 3 SOL-R trial.
Tests AXPAXLI, an eye implant for wet AMD, in the Phase 3 SOL-R trial.
OLMAOlema Pharmaceuticals	Tests palazestrant, a breast cancer pill, in the Phase 3 OPERA-01 trial.	$7.08+1.07%	+1.07%	$641M
Tests palazestrant, a breast cancer pill, in the Phase 3 OPERA-01 trial.
Tests palazestrant, a breast cancer pill, in the Phase 3 OPERA-01 trial.

Show all 14

14 more ranked, for Pro members. See them free →

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See all 17 small-cap biotech stocks rankedSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Why small-cap biotech stocks are up this week

Small-cap biotech stocks rose a median 1.4% since the close on Oct 26 (17 stocks); the S&P 500 fell 1.8%.

What moved them

No single story: 9 of 17 rose this week.

Up most

CAPRCapricor Therapeutics+27%this week
For Pro members
OLMAOlema Pharmaceuticals+6.9%this week
For Pro members
ANNXAnnexon+6.5%this week
For Pro members

3 stocks' stories, for Pro members. See them free →

What moved today

Small-cap biotech stocks are down 1.8% on average, 13 of 17 down.

The news behind each move, for Pro members. See them free →

The week, against the S&P 500

What's next

Earnings reports and FDA dates across small-cap biotech stocks, the next 30 days

EarningsOCSOculis Holding reports, after the close
EarningsMLYSMineralys Therapeutics reports, after the close
EarningsNUVBNuvation Bio reports, after the close

14 more dates, for Pro members. See them free →

What moves small-cap biotech stocks

One result can move these stocks far up or down, and many need cash to keep going.

FDA decisions and committee votes
Phase 3 trial results
Cash on hand, and share sales to raise more

Here is what Pro members see.

The same page for Pro members, on AI chips
Each stock's price, move, next report, and Quality Score, live, with what it does in the theme.
The theme in the scanner
Pick Small-cap biotech under Theme in the scanner's filters, then narrow it by score, size, or any other filter.
An optional theme alert
An optional alert when a small-cap biotech stock reaches Excellent, by push, email, or the bell.
Why a stock ranks
Its Quality Score, its rank, and the reasons behind it, on one card.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
The chart
Candles or lines, the averages you pick, extra panes, and a day to the full history.
The score, added up
Price action, the company, and signals, each with its points, summed into one number on every stock's page.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Questions about small-cap biotech stocks

Why are small-cap biotech stocks up this week?

Small-⁠cap biotech stocks rose a median 1.4% since the close on Oct 26 (17 stocks); the S&P 500 fell 1.8%. No single story: 9 of 17 rose this week.

Which small-cap biotech stocks rose most this week?

Capricor Therapeutics (CAPR) rose 27%, Olema Pharmaceuticals (OLMA) rose 6.9%, and Annexon (ANNX) rose 6.5%.

How many small-cap biotech stocks are there?

This list has 17. A stock is on it when it develops drugs, it was worth under $2 billion when the list was checked, and an FDA decision date, an FDA committee meeting, or a Phase 3 trial data date of its own drug falls in the next 90 days, by its filings or the trial registry. Left out: drug makers worth $2 billion or more, a partner's dates, trials that only extend an earlier study or check safety, and companies that mainly sell approved drugs when the date ahead is a new use for one of them.

Which small-cap biotech stocks does Breakaway rank highest?

Vir Biotechnology (VIR) 5, Biohaven (BHVN) 1, and Agios Pharmaceuticals (AGIO) 1, the highest Quality Scores of the 17. Breakaway ranks every stock by its Quality Score, which reads each company's numbers and its chart; the ranking is information, not advice, and each stock's page shows the reasons behind its score.

Which small-cap biotech stocks are under $5?

6 of the 17 traded under $5 at the prices on this page: Lexicon Pharmaceuticals (LXRX) at $1.44, NRX Pharmaceuticals (NRXP) at $2.18, Vanda Pharmaceuticals (VNDA) at $3.88, Annexon (ANNX) at $3.94, Nuvation Bio (NUVB) at $4.62, and Savara (SVRA) at $4.72.

Which small-cap biotech stocks pay a dividend?

None of the 17 paid a regular cash dividend in the last 12 months.

Is there an ETF for small-cap biotech stocks?

Yes, for one: the SPDR S&P Biotech ETF (XBI) holds biotech stocks of every size. This list is the companies themselves, each one ranked by its Quality Score.

Do these small-cap biotech stocks trade in the US?

Yes. All 17 trade on US stock exchanges, in US dollars. One is a company from outside the US: Oculis Holding (OCS).

Related: GLP-1 and obesity drugs. Every FDA date and trial data date is on the FDA calendar. More in healthcare stocks, or every theme.

Use this page

Kept by Andrew Gomes, Breakaway's founder, from Breakaway's Quality Scores and the market's prices. Updated Nov 2, 2026.

Free to reuse with a link to this page.

How to cite

Breakaway, Small-Cap Biotech Stocks List: 17 Companies, Ranked, Nov 2, 2026, getbreakaway.com/themes/small-cap-biotech

Journalists: email support@getbreakaway.com for the data behind this page.

Every one of the 17, ranked.

Real-time prices, each stock's Quality Score, the theme's score over 60 sessions, every date ahead, the filing behind each company, and optional alerts.

See all 17 small-cap biotech stocks ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.